At Avanti Research, we empower scientific discovery and therapeutic innovation with industry-leading lipid-based solutions and advanced research tools. Built on a 50-year legacy of excellence, we are trusted by researchers worldwide for consistent quality, deep expertise, and a comprehensive portfolio that supports cell biology, drug delivery, membrane science, and biomolecular research. From high-purity lipids and cutting-edge fluorescent probes to tailored formulation service, Avanti Research delivers reliable reagents and collaborative support that help scientists accelerate breakthroughs — from fundamental studies to translational impact. Discover the difference precision, performance, and partnership can make.
AutoGen, Inc.
AutoGen offers expert DNA/RNA extraction solutions for both high- and low-volume labs, including outsourced processing services, highly customizable automated instruments, and consumable kits. Our solutions help biobanks, universities, contract research organizations (CROs), and diagnostic centers increase DNA and RNA processing throughput, meet commitments, and advance the business of science. Workflows: Our instrumentation and consumables are configured to yield the most significant amount of usable nucleic acid. AutoGen workflows include Magnetic Bead-Based Isolation, Column-Based Isolation, and Precipitation-Based Isolation. Extraction Services: Looking for a customized and flexible extraction provider? We offer specialized laboratory services for the extraction of DNA and RNA. Access the latest in automated extraction equipment, chemistries, and protocols from a team of US-based extraction experts dedicated to your project’s success. Sample Storage, ID, and Handling: As the North American distributor of LVL Technologies, we offer a wide array of advanced sample storage solutions, including 2D barcoded tubes, barcode readers, decapping and recapping tools, and other essential equipment. By incorporating these products, labs can reduce sample handling times, ensure optimal sample security, and minimize costly misidentification errors. Saliva & Microbiome Collection: AutoGen is the U.S. partner for Isohelix products, including DNA & RNA saliva collection devices. Contact us to discover how Isohelix products can assist with sample collection, preservation, and isolation. Visit www.AutoGen.com for more details.
AURIGENE PHARMACEUTICAL SERVICES LIMITED
Aurigene Pharmaceutical Services Limited is a leading contract research, development, and manufacturing organization (CRO/CDMO) and a long-term partner providing end-to-end solutions thereby accelerating innovation. With a strong legacy of services in discovery chemistry, discovery biology, development and manufacturing we are ideally positioned to serve global pharma and specialty companies worldwide by providing truly integrated services. We handle both small molecule and large-molecule services across various complex technology platforms and niche technologies. We have access to FDA-inspected dedicated R and D centers in India and cGMP sites across India, UK and Mexico. Beyond science, our operations are rooted in the fundamental principles of compliance, information security, quality and sustainability. | Aurigene Pharmaceutical Services is leading contract research, development, and manufacturing organization (CDMO). Built on the legacy of accelerating innovation and backed by a vast experience in drug discovery and development our mission is to relentlessly work for the success of our clients and to build long term relationships through a holistic approach to accelerate the journey of a molecule from laboratory to market. By providing access to our resources, knowledge and experience, we create success for our clients and ultimately patients. We offer integrated and standalone services for medicinal chemistry, biology, preclinical services, DMPK studies, development and manufacturing for clinical phase I-III programs, regulatory submission batches and commercial manufacturing. A differentiating factor is the integrated API and formulations service that spans from key starting material, advanced intermediates, APIs to finished products such as oral solids, sterile products, nasal solutions etc. Our development services in India are complemented by cGMP commercial manufacturing facilities in the UK, Mexico, USA and India.
AtaGenix Laboratories
AtaGenix is a leading contract research organization (CRO) founded in 2011, specializing in antibody and protein development services for research, diagnostics, and therapeutic R&D. Our expertise spans Single B cell, phage display, nanobody discovery, and stable cell line generation. In 2023, we launched our catalog brand, abinScience, to provide premium life science reagents that accelerate discovery. With over 14 years of proven experience and innovative solutions, AtaGenix delivers high-quality, reliable products and services to researchers worldwide.
ASTRAZENECA
We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. | AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. www.astrazeneca-us.com | . | AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. | AstraZeneca in CVRM; Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way towards regenerative therapies. The Company’s ambition is to improve and save the lives of millions of people, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, diagnose and treat people earlier and more effectively. AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Astellas Pharma US, Inc.
Astellas is committed to turning science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.
Ardigen
Ardigen is your end-to-end trusted partner in the data-to-insights enablement journey that powers modern, AI-data-driven drug discovery. We help life science organizations transform fragmented, multimodal biomedical data into AI-ready foundations, actionable insights, and scalable discovery workflows. Our approach bridges the gap between data potential and discovery impact, grounded in a science-first model that starts with the biological question and aligns every step to measurable, real-world scientific outcomes. | Ardigen, a world-leading AI CRO, stands at the forefront of enabling AI transformation for the biotech and pharmaceutical sectors. Our objective is to increase the probability of success in the drug development process. We utilize our advanced platforms and deep expertise to turn vast amounts of data into pivotal, ready-to-use scientific insights. Leveraging our expertise, we also enhance the infrastructure that allows our clients to integrate and utilize these capabilities seamlessly within their organizations. | Ardigen is a leading AI Contract Research Organisation (CRO) dedicated to increasing the success rate of drug discovery. Recognized among the top 5% of AI in drug discovery companies worldwide, Ardigen integrates expertise in biology, bioinformatics, machine learning, and software engineering to deliver advanced computational solutions exclusively tailored for the biotechnology and pharmaceutical sectors. Over the past 10 years, we have earned the trust of over 120 clients, including 15 major pharmaceutical companies, by providing exceptional in silico research and data engineering services.
Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. | We are delivering meaningful advances for patients with serious diseases who previously had few, or no, approved treatment options. Our medicines are making a difference for patients with: -Geographic atrophy (GA) – a leading cause of blindness -C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) – two severe, rare kidney diseases -Paroxysmal nocturnal hemoglobinuria (PNH) – a rare, life-threatening blood disorder. And we believe we have only begun to unlock the full potential of targeting C3 for patients. With perseverance and passion, we have advanced two C3-targeting medicines from discovery through development and commercialization. Today, we are leveraging our complement expertise to develop new treatments for patients living with serious diseases.